AdaptResponse Clinical Trial

Not Applicable

Completed

Conditions: Heart Failure With Left Bundle Branch Block

Registration Number: NCT02205359

Lead Sponsor: Medtronic Cardiac Rhythm and Heart Failure

Brief Summary: The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 3797

Inclusion Criteria

Subject is willing to sign and date the study Patient Informed Consent Form.
Subject is indicated for a CRT device according to local guidelines.
Sinus Rhythm at time of enrollment
Complete Left Bundle Branch Block (LBBB) as documented on an ECG (within 30 days prior to enrollment). Strauss Criteria used for LBBB.
Intrinsic, normal AV conduction as documented on an ECG by a PR interval less than or equal to 200ms (within 30 days prior to enrollment).
Left ventricular ejection fraction less than or equal to 35% (documented within 180 days prior to enrollment).
NYHA class II, III or IV (documented within 30 days prior to enrollment) despite optimal medical therapy. Optimal medical therapy is defined as maximal tolerated dose of Beta-blockers and a therapeutic dose of ACE-I, ARB or Aldosterone Antagonist.

Exclusion Criteria

Subject is less than 18 years of age (or has not reached minimum age per local law).
Subject is not expected to remain available for at least 2 years of follow-up visits.
Subject has permanent atrial arrhythmias for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted
Subject is, or previously has been, receiving cardiac resynchronization therapy.
Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
Subject has unstable angina, or experienced an acute myocardial infarction (MI) or received coronary artery revascularization (CABG) or coronary angioplasty (PTCA) within 30 days prior to enrollment.
Subject has a mechanical tricuspid heart valve or is scheduled to undergo valve repair or valve replacement during the course of the study.
Subject is post heart transplant (subjects on the heart transplant list for the first time are not excluded).
Subject has a limited life expectancy due to non-cardiac causes that would not allow completion of the study.
Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to device implant).
Subject meets any exclusion criteria required by local law.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation	from subject randomization until the first occurrence of death or intervention for heart failure decompensation, median follow-up 4.9 years (max. follow-up 8.1 years)	The first occurrence of death or intervention for heart failure decompensation (defined as an event requiring invasive intervention or inpatient hospitalization).

Secondary Outcome Measures

Name	Time	Method
All-cause Mortality	from subject randomization until the occurrence of death, median follow-up 4.9 years (max. follow-up 8.1 years)	All-cause mortality in the aCRT ON group vs the aCRT OFF group
Atrial Fibrillation	from subject randomization until the first occurrence of atrial fibrillation lasting >6 hours in one day, median follow-up 4.9 years (max. follow-up 8.1 years)	Occurrence of atrial fibrillation lasting \>6 hours in one day
Change in Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)	from baseline to 24M follow up	The overall summary score of the Kansas City Cardiomyopathy Questionnaire will be analyzed. The KCCQ measures Quality of Life on a 0-100 scale with higher scores indicating better QoL
Change in Quality of Life Measured by the EQ-5D	from baseline to 24M follow up	The EQ-5D descriptive system comprises the following five dimensions, each describing a different aspect of health: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN /DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has three levels: no problems, some problems, extreme problems (labelled 1-3). We calculated the EQ-5D summary index by applying a specific formula providing a valuation to the health states (Shaw et al. Medical Care 2005). For the summary index, value 0 represents health that is valued as equal to death and value 1 represents best possible health.
All-cause Re-admissions Within 30 Days After a Heart Failure Admission Per 100 Patient Years	from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years)	All-cause hospital re-admissions within 30 days after discharge from a heart failure admission are reported as number of cases per 100 patient years
Clinical Composite Score	CCS at 6 month post randomization	The Clinical Composite Score (CCS) classifies patients according their clinical status at 6 months post randomization into categories Improved, Unchanged, and Worsened. A patient is classified Worsened in case of death, hospitalization for worsening heart failure, worsened NYHA class (using last observation carried forward), or worsened status on the Global Assessment Score. Also patients that exit the study or cross over because of worsening heart failure are classified Worsened. A patient is classified Improved when not Worsened and there is an improvement in NYHA class or Global Assessment Score. Patients that are not Worsened or Improved are Unchanged.
Percent of Patients With Interventions for Heart Failure Decompensation	from subject randomization until the first occurrence of intervention for heart failure decompensation, median follow-up 4.9 years (max. follow-up 8.1 years)	First occurence of intervention for heart failure decompensation is defined as an event requiring invasive intervention or inpatient hospitalization.

Trial Locations

Locations (220): CardioVascular Associates of Mesa
🇺🇸
Mesa, Arizona, United States
Phoenix Cardiovascular Research Group, LLC
🇺🇸
Phoenix, Arizona, United States
Saint Vincent Heart Clinic Arkansas
🇺🇸
Little Rock, Arkansas, United States
Scripps Green Hospital Scripps Clinic Torrey Pines
🇺🇸
La Jolla, California, United States
Cedars-Sinai Medical Center
🇺🇸
Los Angeles, California, United States
Coggins & Levy Medical Associates
🇺🇸
San Jose, California, United States
Stanford Hospital & Clinics
🇺🇸
Stanford, California, United States
Saint Joseph's Medical Center
🇺🇸
Stockton, California, United States
Penrose Hospital
🇺🇸
Colorado Springs, Colorado, United States
Medical Center of the Rockies
🇺🇸
Loveland, Colorado, United States
Scroll for more (210 remaining)
CardioVascular Associates of Mesa
🇺🇸Mesa, Arizona, United States